Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Ceapro Inc V.CZO

Ceapro Inc. is a Canada-based biotechnology company. The Company is involved in the development of extraction technology and the application of this technology to the production of extracts and active ingredients from oats and other renewable plant resources. Its primary business activities relate to the development and commercialization of natural products for personal care, cosmetic, human, and animal health industries using technology, natural, renewable resources, and developing products, technologies, and delivery systems. The Company's products include a commercial line of natural active ingredients, including beta glucan, avenanthramides (colloidal oat extract), oat powder, oat oil, oat peptides, and lupin peptides, a commercial line of natural anti-aging skincare products, utilizing active ingredients, including beta glucan and avenanthramides and veterinary therapeutic products, including an oat shampoo, an ear cleanser, and a dermal complex/conditioner.


TSXV:CZO - Post by User

Post by fossi_2002on Mar 08, 2024 3:41am
148 Views
Post# 35922069

Why is AEZS trading below the cash value?

Why is AEZS trading below the cash value?Why is AEZS trading below the cash value?

Novo Nordisk returned license for macimorelin in U.S. and
Canada

Sales of Macrilen ® for adult use in U.S. temporarily
discontinued as of May 23, 2023

Robust business development
efforts to identify and secure a
commercialization partner

Strong cash position with cash projected to fund operations and advancement of priority pipeline programs into 2025 (based on management´s current expectations and planned development avtivities)


Why does it take so long to find a new partner for the US market?

When AEZS runs out of money in 2025, it should be clear to everyone why they need Ceapro's pipeline.

No matter how much Proph writes about possible milestone payments.
This data does not come from the future, but from the current presentation by AEZS itself.
On a positive note, shareholders are kept up to date on the homepage.

At Ceapro, for example, the presentation page has been referring to the following for months: coming soon - the only question is: when is soon?




<< Previous
Bullboard Posts
Next >>